Intrathecal methotrexate in combination with systemic chemotherapy in glioblastoma patients with leptomeningeal dissemination: A retrospective analysis

Table 3 Univariate Cox regression models from diagnosis of leptomeningeal disease to death according to treatment

Covariate	χ2	P value
Sex	< 0.001	0.99
Extent of resection of GBM at diagnosis	5.236	0.022
Communicating with the ventricle at time of GBM diagnosis	0.08	0.778
MGMT methylation	1.743	0.187
TERT C228T mutation	0.811	0.368
Adjuvant TMZ cycles for GBM	0.153	0.695
Bevacizumab	2.963	0.085
KPS at the time of LMD diagnosis	9.192	0.002
Total protein in the CSF	0.986	0.321
Ommaya reservoir implant	12.701	< 0.001
CSF cytology	3.28	0.07

GBM: Glioblastoma; CSF: Cerebral spinal fluid; LMD: Leptomeningeal disease; KPS: Karnofsky performance status; MTX: Methotrexate; DDP: Cisplatin; CBP: Carboplatin; MRI: Magnetic resonance imaging; TERT: Telomerase reverse transcriptase; MGMT: O6-methylguanine-DNA methyltransferase; TMZ: Temozolomide.